Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.61% and Operating profit at 31.49% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 10.94%, it has a attractive valuation with a 1.48 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 14,254 Million (Large Cap)
14.00
NA
4.52%
-0.70
10.94%
1.48
Revenue and Profits:
Net Sales:
1,046 Million
(Quarterly Results - Mar 2026)
Net Profit:
303 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.33%
0%
-6.33%
6 Months
-0.64%
0%
-0.64%
1 Year
-11.4%
0%
-11.4%
2 Years
2.55%
0%
2.55%
3 Years
40.9%
0%
40.9%
4 Years
-12.64%
0%
-12.64%
5 Years
-49.2%
0%
-49.2%
Chengdu Kanghong Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.61%
EBIT Growth (5y)
31.49%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.51
Tax Ratio
12.21%
Dividend Payout Ratio
55.45%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.39%
ROE (avg)
9.96%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.48
EV to EBIT
6.53
EV to EBITDA
5.63
EV to Capital Employed
2.61
EV to Sales
1.70
PEG Ratio
NA
Dividend Yield
4.52%
ROCE (Latest)
39.88%
ROE (Latest)
10.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,046.50
961.30
8.86%
Operating Profit (PBDIT) excl Other Income
343.00
166.10
106.50%
Interest
0.00
0.00
Exceptional Items
0.20
1.30
-84.62%
Consolidate Net Profit
303.20
124.40
143.73%
Operating Profit Margin (Excl OI)
327.80%
107.80%
22.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 8.86% vs -17.85% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 143.73% vs -58.44% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,550.00
4,417.20
3.01%
Operating Profit (PBDIT) excl Other Income
1,498.20
1,465.20
2.25%
Interest
0.40
0.40
Exceptional Items
8.50
0.30
2,733.33%
Consolidate Net Profit
1,145.50
1,177.00
-2.68%
Operating Profit Margin (Excl OI)
275.70%
278.80%
-0.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.01% vs 12.56% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -2.68% vs 14.15% in Dec 2024
About Chengdu Kanghong Pharmaceutical Group Co., Ltd. 
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






